4-mercapto-phenyl-acetic acid ethyl ester | 55863-28-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯硫酚类
• 英文名称: 4-mercapto-phenyl-acetic acid ethyl ester
• 英文别名: ethyl 2-(4-mercaptophenyl)acetate；ethyl (4-mercaptophenyl)acetate；ethyl 4-mercaptophenylacetate；(4-mercapto-phenyl)-acetic acid ethyl ester；(4-mercapto-phenyl)acetic acid ethyl ester；ethyl 2-(4-sulfanylphenyl)acetate
• CAS: 55863-28-0
• 化学式: C₁₀H₁₂O₂S
• 分子量: 196.27
• InChiKey: VSQDDIXLPKYJPG-UHFFFAOYSA-N

物化性质

• 沸点：
  291.6±15.0 °C(Predicted)
• 密度：
  1.145±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  13
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  27.3
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4-mercapto-phenyl-acetic acid ethyl ester 在 三甲基氯硅烷 、 potassium nitrate 作用下， 以 二氯甲烷 为溶剂， 反应 24.0h， 生成 ethyl 2-(4-(chlorosulfonyl)phenyl)acetate
  参考文献：
  名称：

  ACETAMIDE DERIVATIVES AS GLUCOKINASE ACTIVATORS, THEIR PROCESS AND MEDICINAL APPLICATION

  摘要：

  乙酰胺衍生物，它们的立体异构体、互变异构体、前药、药用可接受盐、多型体、溶剂合物及其配方，用于预防、管理、治疗、控制疾病和/或医疗状况的进展，或者作为激活葡萄糖激酶有益时的辅助治疗，已被披露。该披露还提供了这些乙酰胺衍生物的制备方法。

  公开号：

  US20100310493A1
• 作为产物：
  描述：

  4-巯基苯基乙酸 以 盐酸 、 乙醇 为溶剂， 生成 4-mercapto-phenyl-acetic acid ethyl ester
  参考文献：
  名称：

  6,11-Dihydro-11-oxo-dibenzo[b,e]thiepine-2-acetic acids

  摘要：

  本发明提供了化合物的公式I，其中R.sub.1是氢、氟、氯、溴、羟基、低烷基、低烷氧基、氨基或低酰胺基，R.sub.2是氢或低烷基，可用作抗炎和抗关节炎药物。

  公开号：

  US03946036A1

文献信息

• Aromatic amidine derivatives and salts thereof
  申请人：Daiichi Pharmaceutical Co., Ltd.

  公开号：US05576343A1

  公开（公告）日：1996-11-19

  An anticoagulant agent which comprises, as an active ingredient, an aromatic amidine derivative represented by the following general formula (1) or a salt thereof: ##STR1## wherein the group represented by ##STR2## is a group selected from indolyl, benzofuranyl, benzothienyl, benzimidazolyl, benzoxazolyl, benzothiazolyl, naphthyl, tetrahydronaphthyl and indanyl; X is a single bond, an oxygen atom, a sulfur atom or a carbonyl group; and Y is a saturated or unsaturated 5- or 6-membered heterocyclic moiety or cyclic hydrocarbon moiety optionally having a substituent group, an amino group optionally having a substituent group or an aminoalkyl group optionally having a substituent group. The inventive compound has a high anticoagulant capacity based on its excellent FXa inhibition activity.

  一种抗凝剂，其包括作为活性成分的芳香胺基衍生物，其由以下一般式（1）或其盐所表示：##STR1## 其中由##STR2##表示的基团是从吲哚基，苯并呋喃基，苯并噻吩基，苯并咪唑基，苯并噁唑基，苯并噻唑基，萘基，四氢萘基和吲哚基中选择的基团；X是单键，氧原子，硫原子或羰基；Y是饱和或不饱和的5-或6-成员杂环基团或环烃基团，可选地具有取代基团，可选地具有取代基团的氨基团或可选地具有取代基团的氨基烷基团。这种创新化合物具有基于其出色的FXa抑制活性的高抗凝能力。
• [EN] ROR GAMMA (RORY) MODULATORS<br/>[FR] MODULATEURS DU ROR GAMMA (RORY)
  申请人：LEAD PHARMA CEL MODELS IP B V

  公开号：WO2015082533A1

  公开（公告）日：2015-06-11

  The present invention relates to compounds according to Formula I: Wherein: A11 - A14 are N or CR11, CR12, CR13, CR14, respectively, with the proviso that no more than two of the four positions A can be simultaneously N; R1 is C(1-6)alkyl, C(3-6)cycloalkyl, C(3-6)cycloalkylC(1 -3)alkyl, (di)C(1-6)alkylamino, (di)C(3-6)cycloalkylamino or (di)(C(3-6)cycloalkylC(1 -3)alkyl)amino, with all carbon atoms of alkyl groups optionally substituted with one or more F and all carbon atoms of cycloalkyl groups optionally substituted with one or more F or methyl; R2 and R3 are independently H, F, methyl, ethyl, hydroxy, methoxy or R2 and R3 together is carbonyl, all alkyl groups, if present, optionally being substituted with one or more F; R4 is H or C(1-6)alkyl; R5 is H, hydroxyethyl, methoxyethyl, C(1-6)alkyl, C(6-10)aryl, C(6-10)arylC(1-3)alkyl, C(1 -9)heteroaryl, C(1-9)heteroarylC(1-3)alkyl, C(3-6)cycloalkyl, C(3-6)cycloalkylC(1 -3)alkyl, C(2-5)heterocycloalkyl or C(2-5)heterocycloalkylC(1-3)alkyl, all groups optionally substituted with one or more F, CI, C(1-2)alkyl, C(1-2)alkoxy or cyano; the sulfonyl group with R1 is represented by one of R7, R8 or R9; the remaining R6-RH are independently H, halogen, C(1-3)alkoxy, (di)C(1-3)alkylamino or C(1-6)alkyl, all of the alkyl groups optionally being substituted with one or more F; and Ri5 and Ri6 are independently H, C(1-6)alkyl, C(3-6)cycloalkyl, C(3-6)cycloalkylC(1-3)alkyl, C(6-10)aryl, C(6-10)arylC(1-3)alkyl, C(1-9)heteroaryl, C(1-9)heteroarylC(1-3)alkyl, C(2-5)heterocycloalkyl or C(2-5)heterocycloalkylC(1-3)alkyl, all groups optionally substituted with one or more F, CI, C(1-2)alkyl, C(1-2)alkoxy or cyano. The compounds can be used as inhibitors of RORy and are useful for the treatment of RORy mediated diseases.

  本发明涉及符合以下式I的化合物：其中：A11 - A14分别为N或CR11，CR12，CR13，CR14，但四个位置A中不超过两个可以同时为N；R1为C(1-6)烷基，C(3-6)环烷基，C(3-6)环烷基C(1-3)烷基，(双)C(1-6)烷基氨基，(双)C(3-6)环烷基氨基或(双)(C(3-6)环烷基C(1-3)烷基)氨基，烷基族的所有碳原子可选择性地被一个或多个F取代，环烷基族的所有碳原子可选择性地被一个或多个F或甲基取代；R2和R3独立地为H，F，甲基，乙基，羟基，甲氧基或R2和R3一起为羰基，所有烷基族（如果存在）可选择性地被一个或多个F取代；R4为H或C(1-6)烷基；R5为H，羟乙基，甲氧乙基，C(1-6)烷基，C(6-10)芳基，C(6-10)芳基C(1-3)烷基，C(1-9)杂环芳基，C(1-9)杂环芳基C(1-3)烷基，C(3-6)环烷基，C(3-6)环烷基C(1-3)烷基，C(2-5)杂环烷基或C(2-5)杂环烷基C(1-3)烷基，所有基团可选择性地被一个或多个F，CI，C(1-2)烷基，C(1-2)烷氧基或氰取代；与R1相连的磺酰基由R7，R8或R9之一表示；其余的R6-RH独立地为H，卤素，C(1-3)烷氧基，(双)C(1-3)烷基氨基或C(1-6)烷基，所有烷基族可选择性地被一个或多个F取代；Ri5和Ri6独立地为H，C(1-6)烷基，C(3-6)环烷基，C(3-6)环烷基C(1-3)烷基，C(6-10)芳基，C(6-10)芳基C(1-3)烷基，C(1-9)杂环芳基，C(1-9)杂环芳基C(1-3)烷基，C(2-5)杂环烷基或C(2-5)杂环烷基C(1-3)烷基，所有基团可选择性地被一个或多个F，CI，C(1-2)烷基，C(1-2)烷氧基或氰取代。这些化合物可用作RORγ的抑制剂，并且对于治疗RORγ介导的疾病是有用的。
• [EN] THIAZOLOPYRIDINE DERIVATES, PHARMACEUTICAL CONDITIONS CONTAINING THEM AND METHODS OF TREATING GLUCOKINASE MEDIATED CONDITIONS<br/>[FR] DERIVES THIAZOLOPYRIDINE, COMPOSITIONS PHARMACEUTIQUES LES CONTENANT ET PROCEDES DE TRAITEMENT DE TROUBLES A MEDIATION PAR GLUCOKINASE
  申请人：NOVARTIS AG

  公开号：WO2005095417A1

  公开（公告）日：2005-10-13

  The present invention provides compounds of the formula (I) which are activators of glucokinase activity and, thus, may be employed as therapeutic agents for the treatment of glucokinase mediated conditions. Accordingly, the compounds of formula (I) may be employed for the prevention and the treatment of impaired glucose tolerance, Type 2 diabetes and obesity.

  本发明提供了一种化合物，其化学式为（I），这些化合物是葡萄糖激酶活性激活剂，因此可以作为治疗葡萄糖激酶介导的疾病的治疗剂。因此，化合物的化学式（I）可用于预防和治疗糖耐量受损、2型糖尿病和肥胖。
• ROR GAMMA (RORY) MODULATORS
  申请人：Lead Pharma Cel Models IP B.V.

  公开号：EP3101007A1

  公开（公告）日：2016-12-07

  The present invention relates to compounds according to Formula I: or a pharmaceutically acceptable salt thereof wherein the variables are as defined in the claims. The compounds can be used as inhibitors of RORγ and are useful for the treatment of RORγ mediated diseases.

  本发明涉及符合以下式I的化合物： 或其药学上可接受的盐，其中变量如权利要求中所定义。这些化合物可用作RORγ的抑制剂，并且对于治疗RORγ介导的疾病是有用的。
• Aminoalcohol derivatives
  申请人：——

  公开号：US20040138462A1

  公开（公告）日：2004-07-15

  The present invention relates to a compound formula wherein R 1 is phenyl, pyridyl, etc., each of which may be substituted with one or two substituent(s); R 2 is hydrogen, an amino protective group, etc.; R 3 and R 4 are each independently hydrogen, lower alkyl or hydroxy(lower)alkyl; R 5 is aryl, ar(lower)alkyl, etc., each of which may be substituted with one, two or three substituent(s); R 8 is hydrogen or halogen, X is a single bond or O—CH 2 —, and n is 0, 1 or 2, or a salt thereof. The compound [I] of the present invention and pharmaceutically acceptable salts thereof are useful for the prophylactic and/or the therapeutic treatment of pollakiurea or urinary incontinence. 1

  本发明涉及一种化合物配方，其中R1是苯基，吡啶基等，每个基团可以用一个或两个取代基取代；R2是氢，氨基保护基等；R3和R4各自独立地是氢，低碳基或羟基（低）碳基；R5是芳基，芳（低）碳基等，每个基团可以用一个、两个或三个取代基取代；R8是氢或卤素，X是单键或O-CH2-，n为0、1或2，或其盐。本发明的化合物[I]及其药学上可接受的盐对预防和/或治疗多尿或尿失禁非常有用。